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The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically
verified malignant pleural mesothelioma (MPM), normal organ function, and performance status 0–2. Treatment was vinorelbine
25mgm
 2 i.v. weekly and cisplatin 100mgm
 2 i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment.
Patients gave written informed consent. Characteristics of 54 consecutive patients were: males 85%, epithelial subtype 74%, IMIG
stages III and IV 35 and 46%, performance status 0, 1, and 2, 26, 69, and 6%, and median age 63 years (31–78 years). CTC grade 3 or
4 toxicity occurred with respect to leukocytopenia (48% of patients, grade 4 in 13%), nausea (13%), neurotoxicity (11%),
nephrotoxicity (4%), and other toxicities (9%). There were no toxic deaths. The median number of cycles was four. The fraction of
patients alive at 1-, 2-, and 3-years were 61, 31, and 4%, respectively, and median survival and median time to progression were 16.8
months (0.5 to 46.4 þmonths) and 7.2 months (1.6 to 40.6 þ months). There were two CRs and 14 PRs (response rate 29.6%).
Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most
active regimens so far reported.
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Malignant pleural mesothelioma (MPM) is a highly aggressive
malignancy whose incidence is increasing throughout the world.
The diffuse spreading growth of this neoplasm makes surgery
difficult and hence an option for only a minority of the patients
(Treasure and Sedrakyan, 2004). The treatment options for the
majority of patients are best supportive care and palliative
chemotherapy (Ceresoli et al, 2006a,b). Chemotherapy for MPM
is challenging, although several cytotoxic agents have been tested
and the rates of objective tumour response have ranged from 10 to
30% with monotherapy (Tomek and Manegold, 2004). Cisplatin
and carboplatin are both active and thus usually included in the
most used combination chemotherapy regimens for MPM
(Sørensen, 2008).
Pemetrexed is a multitargeted antifolate with a 14% response
rate as a single agent in chemotherapy-naive MPM patients
(Scagliotti et al, 2003). A recent randomised trial showed that
combination chemotherapy with pemetrexed and cisplatin was
superior to cisplatin single-agent treatment with respect to both
time to progression and overall survival (Vogelzang et al, 2003).
Raltitrexed is another antifolate tested in combination with
cisplatin against cisplatin alone in a randomised trial (van
Meerbeeck et al, 2005). The combination was superior compared
to cisplatin alone with respect to time to progression but not with
respect to overall survival. A recent randomised study compared
active symptom control (ASC) alone to ASC plus vinorelbine and
to ASC plus mitomycin plus vinblastine plus Cisplatin (Muers
et al, 2007). The impact of chemotherapy on symptom control and
quality of life have been evaluated in both of these randomised
trials, pointing towards an improvement with respect to dyspnoea
and stabilisation with respect to other parameters (Boyer et al,
2003; Bottomley et al, 2006). The activity of the chemotherapy is
still modest, and hence novel agents need to be evaluated for use in
combination chemotherapy regimens for improvement of outcome
(Green et al, 2007).
A large number of single agents have been tested for activity in
MPM (Berghmans et al, 2002; Ellis et al, 2006; Sørensen, 2008). The
third generation vinca alkaloid vinorelbine has attracted interest
in a phase II trial using vinorelbine 30mgm
 2 i.v. weekly (Steele
et al, 2000). A cycle consisted of 6 weekly injections and the
median number of injections was 12. The intention-to-treat
response rate among 29 chemotherapy-naive MPM patients was
24% (95% confidence level 10–44%) and the fraction of patients
alive 1 year from time of first treatment was 41%, which ranks
vinorelbine among the most active agents in MPM. Toxicity was
modest. On the basis of these results, it seems interesting and
feasible to evaluate the activity of vinorelbine together with
cisplatin. The feasibility and tolerability of this doublet is already
very well known from its use in non-small cell lung cancer
(NSCLC) in which it is among the most active regimens. Both the
South West Oncology Group (SWOG) and the French group have
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spublished their data on activity and toxicity in NSCLC using
cisplatin 100mgm
 2 every 4 weeks together with weekly i.v.
vinorelbine 25mgm
 2 (Wozniak et al, 1998) or cisplatin
120mgm
 2 every 4–6 weeks together with weekly i.v. vinorelbine
30mgm
 2 (LeChevalier et al, 1994). Accordingly, the purpose of
this study was to evaluate this regimen cisplatin and vinorelbine
for its activity as first-line treatment in MPM using the regimen by
SWOG.
MATERIALS AND METHODS
Patients
Eligibility criteria included histologically proven MPM, no
previous chemotherapy, inoperable for anatomical or for physio-
logical reasons, measurable disease, ECOG performance status
0–2, estimated survival expectancy of X3 months, age X18 years,
and written informed consent.
Adequate organ functions were required, defined as WBC
X3000ml
 1, platelets X100000ml
 1, haemoglobin X9.0g per
100ml, bilirubin o1.25 times upper limit of normal, AST and
ALT o2.5 times upper limit of normal, and creatinine o2.0mg
per 100ml. The renal function measured as a chrome-EDTA
clearance had to be within normal limits.
Exclusion criteria included: Significant medical or psychiatric
co-morbidity, central nervous metastases, pregnant or lactating
women, and history of previous cancers in the previous 5 years or
breast cancer ever. All patients of fertile capacity were to use safe
contraception. The standards of Helsinki Declaration were
fulfilled.
Treatment
Cisplatin 100mgm
 2 was administered as a 1-h i.v. infusion
together with intravenous hydration 1l of normal saline before and
after infusion and with standard antiemetic treatment using
metoclopramide, prednisolone, and ondansetron every 4 weeks.
Vinorelbine 25mgm
 2 was administered i.v. weekly as a 10-min
infusion without routine antiemetic treatment. Weekly complete
blood cell counts and chemistry panel were performed, and
treatment was delayed by 1 week in the event of bone marrow
suppression (WBC o3000ml
 1, neutrophile count o1500ml
 1 or
platelets o100000ml
 1). No cisplatin was administered in case of
decline in renal clearance to either severely reduced or less than
50mlmin
 1. The patients did not receive vitamin substitution.
Dose was adjusted for grade 4 haematological toxicity, or grade
3 or 4 non-haematological effects were done. Dose delays up to 3
weeks were permitted for recovery from study drug toxicity. Dose
escalations were not allowed. Granulocyte colony-stimulating
factors were not routinely used.
Assessments during treatment
Baseline and predosing assessments included complete history and
physical examination, complete blood cell count, liver enzymes,
blood electrolytes, blood albumin, calcium, and glucose. Measuring
of renal function as chrome-EDTA clearance was performed at
baseline and then before every second treatment cycle (every 8
weeks).
Spiral CT-scan was performed at baseline, before start of every
other treatment cycle (every 8 weeks), and every 2 months after
completion of study therapy. Chest X-ray was performed at
baseline and before each treatment cycle. The staging system as
defined by the International Mesothelioma Interest Group (IMIG)
was used (Rusch, 1995). The new modified RECIST criteria for the
assessment of response in MPM were applied (Byrne and Nowak,
2004). Change in disease was assessed by measuring the tumour
thickness perpendicular to the chest wall or mediastinum in up to
three involved areas of pleural rind at least 2cm apart on
computed tomography scan, at baseline, and at every other cycle
(at least one measurement was 41.5cm). A reduction of at least
30% on two occasions 4 weeks apart defined a partial response; an
increase of 20% over the nadir measurement, progressive disease.
A complete response (CR) was defined as the complete absence of
all signs of disease without any new lesions or disease-related
symptoms.
Survival was defined as the time from onset of treatment to the
time of death from any cause. Time to progressive disease was
defined as the time from onset of treatment until documented
progression or death from any cause. For patients without any
progression at the time of analysis, the date of last follow-up was
considered right-censored.
Statistical considerations
The current regimen was the only standard treatment available for
this patient group at the time because pemetrexed was unavailable.
Hence, it was not a formal phase II trial, though the treatment was
approved by the participating institutions’ local ethical committees
and was prospective with the aim of data collection on predefined
case report forms. Statistical analysis was to be done according to
the Gehan one sample, two stage model (Gehan, 1961). Type I and
type II errors were set at 5 and 20% and a minimum response rate
of 20% would be of clinical interest in this population. Under this
hypothesis, a total sample of at least 40 patients was required, but
interim analysis at 14 evaluable patients would be performed to
discontinue the study if 0 or 1 response was observed. To
compensate for possible ineligibilities, some extra patients could
be included. Kaplan–Meier curves were used to estimate the
overall survival and time to progression.
RESULTS
Patients’ characteristics
Fifty-four consecutive patients were enrolled from February 2003
to September 2006. Most patients were males (85%), had epithelial
subtype (74%), performance status 0–1 (94%), previous asbestos
exposure (76%), and IMIG stages III–IV (81%) (Table 1). Median
age was 63 years (range 31–78 years). Median lead time from
initial diagnosis to start-of-study therapy was 52 days (range
1–118 days).
Toxicity
A total of 204 treatment courses were administered, with a median
of 4 (range 1–6). CTC grade 3 or 4 toxicity occurred with respect
to leukopenia in 26 patients (48%), with 6 patients having grade 4
(11%) (Table 2). Five patients (9%) experienced febrile leukopenia
and no septic deaths were encountered. None had grade 3 or 4
thrombocytopenia. Non-haematological grade 3 or 4 toxicity
occurred with respect to nausea (13%), neurotoxicity (11%),
nephrotoxicity (4%), and other toxicities such as tiredness or
constipation in 9%. Nine patients (17%) were hospitalised owing
to toxic effects of chemotherapy. One patient died within 30 days
of treatment start owing to a pulmonary embolism.
Treatment intensity is shown at Table 3. The patients received
in median 4 treatment courses and 80.4 and 77.2%, respectively,
of planned cisplatin and vinorelbine doses. Dose reductions were
necessary in 19 patients (35%), most frequently due to haemato-
logic toxicity (15 patients) or nephrotoxicity (5 patients).
Other less frequent causes were nausea, tinnitus, and hearing
loss. These reasons were non-exclusive. Retreatment postpone-
ment due to delayed haematological recovery occurred in 21
patients (39%). Non-exclusive reasons were delayed haematologic
Cisplatin and vinorelbine in MPM
JB Sørensen et al
45
British Journal of Cancer (2008) 99(1), 44–50 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
srecovery (10 patients), haematuria, pneumonia, and poor perfor-
mance status.
Response and survival
Partial response and CRs occurred in 14 patients (25.9%) and 2
patients (3.7%), respectively, with an overall response rate of
29.6% (95% confidence limits 18.0–43.6%) (Table 4). A case of
heavy tumour burden with regression after three treatment courses
is shown in Figures 1 and 2. Thirteen responses occurred among
the 40 cases having epithelial subtype (32.5%) and in two and one
patients, respectively, among the five sarcomatous and nine
biphasic cases. Four responses were noted among 8 female
patients (50%) compared to 12 responses among 46 males (26%)
(P¼0.45).
The fractions of patients alive after 1 and 2 years were 61 and
31%, respectively (Table 4). Time to progression was in median 7.2
months, whereas median overall survival was 16.8 months.
Curves of overall survival and time to progression are shown in
Figures 3 and 4, respectively.
Post-study treatment
A total of 22 patients (41%) received second-line chemotherapy
(Pemetrexed 20 patients; carboplatinþcaelyxþgemcitabine 2
patients). Seven patients received palliative irradiation.
DISCUSSION
This report provides data on the use of a combination of cisplatin
and vinorelbine in chemotherapy-naive patients having inoperable
MPM. The response rate of 29.6% is noteworthy, being comparable
to the most used regimens in MPM (Table 4). It is, however,
not possible to draw firm conclusions concerning major
differences in activity between these regimens for several reasons.
First, the majority are either phase II trials or retrospectively
Table 2 Worst toxicity (CTC grading) in 54 MPM patients receiving
cisplatin and vinorelbine
No. of patients (%)
CTC grades 0123 4
Variables
Leukocytes 6 (11) 4 (7) 18 (33) 19 (35) 6 (11)
Neutrophils 8 (15) 7 (13) 19 (35) 15 (28) 5 (9)
Thrombocytes 50 (93) 3 (5) 1 (2) — —
Nausea 19 (35) 21 (39) 7 (13) 7 (13) —
Vomiting 31 (57) 12 (22) 11 (20) — —
Nephrotoxicity 26 (48) 12 (22) 14 (26) 2 (4) —
Neurotoxicity 22 (41) 16 (30) 10 (19) 4 (7) 2 (4)
Other toxicity 4 (7) 24 (44) 21 (39) 4 (7) 1 (2)
Table 3 Intensity of treatment for 54 inoperable MPM patients treated
with cisplatin and vinorelbine
Variables
No. of treatment courses No. of patients (%)
1 8 (15)
2 8 (15)
3 8 (15)
4 10 (19)
5 4 (7)
6 16 (30)
Cumulative dose mgm
 2week
 1
Cisplatin 20.1 (80.4%)
a
Vinorelbine 19.3 (77.2%)
a
aPercentage of cumulative dose relative to planned dose.
Table 4 Efficacy of cisplatin and vinorelbine in 54 inoperable MPM
patients
Variables No. of patients (%)
Dead
No 12 (22)
Yes 42 (78)
Fraction alive
1 year 33 (61)
2 years 17 (31)
Survival
Median 16.8 months
(range) (0.5 to 46.4+ months)
Response
CR 2 (3.7)
PR 14 (25.9)
NC/PD 38 (70.4)
Time to progression
Median 7.2 months
(range) (1.6 to 40.6+ months)
Table 1 Characteristics of 54 MPM patients treated with cisplatin and
vinorelbine
Variables No. of patients (%)
Total 54 (100)
Gender
Male 46 (85)
Female 8 (15)
Asbestos exposure
No 11 (22)
Yes 41 (76)
NA 2 (4)
Histology
Epithelial 40 (74)
Sarcomatous 5 (9)
Biphasic 9 (17)
IMIG stage
Ia 1 (2)
Ib 1 (2)
II 8 (14)
III 19 (35)
IV 25 (46)
Performance status
0 14 (26)
1 37 (69)
2 3 (6)
Age
Median 63 years
Range (31–78 years)
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sanalyses except for the randomised trials by Vogelzang et al,
2003, and van Meerbeeck et al, 2005, which may not be entirely
comparable as there is usually a tendency towards higher
response rates observed in the very selective non-randomised
trials. Another source of variability is the different mixture of
various prognostic variables between the trials. Both analyses of
prognostic variables by CALGB in 337 patients (Herndon et al,
1998), by EORTC in 204 patients (Curran et al, 1998), and in the
randomised trial by van Meerbeeck et al in 250 patients pointed
towards a better outcome for MPM patients having the epithelial
histological subtype. A worse prognosis was reported for patients
in poor performance status or advanced age. Independent
predictors of survival in CALGB study were performance status,
age, chest pain, weight loss, leukocyte count, and haemoglobin
level, whereas they were histology, performance status, gender, and
leukocyte count in the EORTC study. The frequency of epithelial
subtype in the current study was 74%, which is somewhat higher
than the around 60% usually considered average in the entire
MPM population (Vogelzang, 2002), thus possibly contributing to
a tendency towards a higher response rate. The frequency of
epithelial subtype was, however, similar to the frequencies in
newer studies, such as those by Vogelzang et al, 2003 (68%
epithelial), van Meerbeeck et al, 2005 (75%), Berghmans et al, 2005
(74%), and van Haarst et al, 2002 (81%), pointing toward a rather
uniform rate of epithelial subtype of 70–80% in more recent trials
for chemotherapy in MPM and with the current study being in
accordance with these trials. Interestingly, the activity is also
comparable to that of single-agent Vinorelbine, which revealed a
24% partial response rate (Steele et al, 2000).
Measurement of tumour response to antineoplastic chemother-
apy is notoriously difficult both when using the WHO and the
RECIST criteria due to the parietal growth patterns of these
tumours (Monetti et al, 2004; van Klaveren et al, 2004). Recently,
modified RECIST criteria for use in MPM have been suggested by
Byrne and Nowak, 2004, measuring tumour thickness perpendi-
cular to the chest wall or mediastinum in two positions at three
separate levels on thoracic CT scans. The use of these different
systems in various reports may contribute to variations in the
response rates observed, in addition to the variations caused by
different distributions of known and unknown prognostic
CT scan before chemotherapy:  
tumour close to aorta 5.7×3.3 cm
CT scan after three courses of cisplatin+ 
 vinorelbine: tumour close to aorta < 0.5 cm
Figure 1 CT scan before and after three courses of cisplatin and vinorelbine in MPM with shrinkage of tumour close to aorta.
CT scan before chemotherapy: tumour close to 
aorta 3.1 cm and peripheral tumour 3.9×3.4 cm
CT scan after three courses of cisplatin+vinorelbine:
tumour close to aorta < 0.5 cm and peripheral  
tumour shrinkage to two tumours < 0.5 cm
Figure 2 Same patients as Figure 1 with CT scan before and after three courses of cisplatin and vinorelbine in MPM with shrinkage of tumours more
distally close to aorta and peripheral tumour.
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svariables and possible differences in activity between the treatment
regimens under evaluation. There is a growing evidence that
therapy-induced changes in tumour FDG uptake, as measured by
FDG-PET imaging, might predict response and patient outcome
(Ceresoli et al, 2007). Thus, FDG-PET imaging could be potentially
useful in the early assessment of treatment efficacy.
Haematological toxicity was relatively pronounced in the
current study of cisplatin and vinorelbine with 48% of patients
having leukopenia CTC grade 3 or 4 (Table 2). This is, however, in
accordance with the 54% grade 3 or 4 leukopenia confined with
cisplatin and epirubicin in MPM (Berghmans et al, 2005) and
lower than the 81% of NSCLC patients who had grade 3 or 4
granulocytopenia in the randomised SWOG trial using same doses
of cisplatin and vinorelbine as the current study (Wozniak et al,
1998). It is, however, considerably higher than was observed in the
randomised trials in MPM patients with cisplatin and pemetrexed
(18%, Vogelzang et al, 2003) or cisplatin and raltitrexed (7%,
van Meerbeeck et al, 2005). Also, the rate of febrile leukopenia was
somewhat higher, being 9% compared to 2 and 1%, respectively, in
the two randomised trials cited above. There were no septic deaths
and no toxic deaths overall, but the febrile lekopenia rate of 9% in
this study is not only a potential risk but also an inconvenience for
those patients who have to be admitted for intravenous antibiotics,
as well as a cost for the health-care system. The use of granulocyte
colony-stimulating factor may diminish the problem but was not a
part of this protocol. Other toxicities were generally not
pronounced (Table 2).
The survival of patients with MPM who received cisplatin and
vinorelbine in this study was impressive with 31% being alive after
2 years and a median survival of 16.8 months, even though patients
with adverse prognostic variables such as performance status 2 and
age above 70 years were included (Table 1). The use of second-line
chemotherapy in 22 patients may possibly have had an impact on
survival. However, these figures are small and there are potential
selection biases in the choice of second-line treatment or not.
Hence, a possible impact cannot be explored or concluded from
these data. The survival results compares favourably with those
reported on for other active regimens, ranking the combination of
cisplatin and vinorelbine among the most active cytotoxic
treatments for MPM reported to date (Table 5). On the other
hand, this regimen is convenient for neither the patients nor for
the health-care system because of the weekly administration of
intravenous vinorelbine and because of the haematological toxicity
encountered. Other regimens in Table 4 may be more convenient
and less troublesome in the palliative treatment setting. A number
of regimens seem to possess similar activity without any regimen
being clearly superior. No combination chemotherapy regimens
have been compared to each other in randomised trials, but the
regimens of both cisplatin and pemetrexed as well as cisplatin and
raltitrexed have proved superior to single agent treatment with
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Figure 3 Kaplan–Meier curve of time to progression in 54 inoperable
MPM patients treated with cisplatin and vinorelbine (median time to
progression, 7.2 months).
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Figure 4 Kaplan–Meier curve of overall survival in 54 inoperable MPM
patients treated with cisplatin and vinorelbine (median overall survival time,
16.8 months).
Table 5 Selected combination chemotherapy regimens in MPM
Author, year Regimen n Response rate (%) Median survival (months) Time to PD (months) 1-year survival (%)
Current study CDDP+vinorelbine 54 29.6 16.8 7.2 61
van Meerbeeck, 2005
a CDDP+raltitrexed 126 24.0 11.4 5.3 46
Vogelzang, 2003
a CDDP+pemetrexed 226 41.3 12.1 5.7 51
Obasaju, 2007 CDDP+pemetrexed 728 20.5 10.8 NA 45
Santoro, 2007 CBDCA+pemetrexed 861 21.7 NA NA 64
Ceresoli, 2006b CBDCA+pemetrexed 102 18.6 12.7 6.5 52
Andreopoulou, 2004 CDDP+MMC+VBL 150 15.3 7.0 NA 31
Byrne, 1999 CDDP+gemcitabine 21 48.0 10.0 NA NA
van Haarst, 2002 CDDP+gemcitabine 32 16.0 9.6 6.0 36
Favaretto, 2003 CBDCA+gemcitabine 50 26.0 14.7 8.9 53
Berghmans, 2005 CDDP+epirubicin 69 19.0 13.3 NA 50
Abbreviations: CDDP¼cisplatin; CBDCA¼carboplatin; MMC¼mitomycin C; VBL¼vinblastine; NA¼not available.
aData from randomised trial.
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scisplatin in randomised trials (Vogelzang et al, 2003; van
Meerbeeck et al, 2005). It is of great importance to use a treatment
regimen with a high antitumour activity in another clinical
situation such as induction chemotherapy before surgery, and
the current regimen may, despite its inconvenience, be among the
options for that situation.
The high activity of cisplatin and vinorelbine deserves attention
for use as induction treatment before surgery in resectable cases.
Further development of platinum compounds, together with
vinorelbine in the palliative setting, also seems justified both in
the light of the documented activity of the two-drug combination
used in the current study and also because the single agent activity
of vinorelbine with a response rate of 24% (Steele et al, 2000) ranks
this agent among the most active single drugs in MPM. It must,
however, be kept in mind that these results are obtained from
relatively small and non-randomised trials with wide confidence
limits. Improvement of the current regimen is necessary if it is to
be used in the palliative situation to make it more feasible and
carboplatin may thus be used instead of cisplatin and vinorelbine
applied in the oral formulation. Further improvement of the
regimen in the palliative setting is under evaluation by the
investigative group. The oral formulation of vinorelbine may
render the regimen more convenient and feasible, and evaluation
of new targeted agents is necessary to improve prognosis for this
dismal disease. Taking the documented activity of vinorelbine in
the first-line treatment of MPM into consideration, vinorelbine
may also be explored as second-line treatment for patients not
previously exposed to this drug.
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